Baxter International

Baxter will buy the Seprafilm adhesion barrier and related assets from Sanofi in a $350 million deal expected to close by Q1 2020.

Baxter International Inc. plans to invest up to $500 million in its U.S. renal care market, including potential new U.S. facilities and additional jobs at existing sites to produce more PD solutions, devices and cassettes.

Medical equipment maker Baxter International is expanding a plant in Cleveland, Mississippi, with plans to add 50 to 100 new employees in about two years.

Toyobo Co., Ltd. signed a sales agreement with Synovis Micro Companies Alliance Inc., a subsidiary of Baxter International, to distribute its nerve regeneration tube NerveBridge in the United States, with sales starting in September 2018.

Baxter International announced an agreement to acquire two hemostat and sealant products, RECOTHROM and PREVELEAK, from Mallinckrodt plc to broaden its surgical portfolio.

Baxter intends to invest in three Claris manufacturing plants with new aseptic manufacturing, lyophilization, and cytotoxics technology platforms.

Baxter International Inc. completed the acquisition of Claris Injectables Limited, a global generic injectables pharmaceutical company, for approximately $625 million, gaining three manufacturing plants and over 50 products.

Baxter International entered a definitive agreement to acquire Claris Injectables Limited, a subsidiary of Claris Lifesciences, for approximately $625 million. The deal is expected to close in the second half of 2017.